Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Inventory (2016 - 2026)

Orthopediatrics has reported Inventory over the past 11 years, most recently at $134.0 million for Q1 2026.

  • For Q1 2026, Inventory rose 11.92% year-over-year to $134.0 million; the TTM value through Mar 2026 reached $134.0 million, up 11.92%, while the annual FY2025 figure was $133.8 million, 14.35% up from the prior year.
  • Inventory for Q1 2026 was $134.0 million at Orthopediatrics, roughly flat from $133.8 million in the prior quarter.
  • Over five years, Inventory peaked at $134.0 million in Q1 2026 and troughed at $64.1 million in Q1 2022.
  • A 5-year average of $104.4 million and a median of $112.7 million in 2024 define the central range for Inventory.
  • Biggest five-year swings in Inventory: skyrocketed 35.82% in 2022 and later increased 6.27% in 2025.
  • Year by year, Inventory stood at $78.2 million in 2022, then skyrocketed by 35.37% to $105.9 million in 2023, then grew by 10.54% to $117.0 million in 2024, then rose by 14.35% to $133.8 million in 2025, then increased by 0.17% to $134.0 million in 2026.
  • Business Quant data shows Inventory for KIDS at $134.0 million in Q1 2026, $133.8 million in Q4 2025, and $128.8 million in Q3 2025.